2. Signaling Pathways
  3. GPCR/G Protein
  4. Angiotensin Receptor
  5. AT2 Receptor Isoform
  6. AT2 Receptor Antagonist

AT2 Receptor Antagonist

AT2 Receptor Antagonists (14):

Cat. No. Product Name Effect Purity
  • HY-P0216
    A 779
    		Antagonist 99.12%
    A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.
  • HY-10259A
    PD 123319 ditrifluoroacetate
    		Antagonist 99.82%
    PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
  • HY-162998
    AT2R antagonist 2
    		Antagonist
    AT2R antagonist 2 (compound I-16) is an orally active AT2R antagonist.
  • HY-117858
    CL-329167
    		Antagonist
    CL-329167 (compound 12) is an orally active and competitive angiotensin II receptor antagonist (IC50=6 nM). CL-329167 can be used in the research of hypertension.
  • HY-13106
    Olodanrigan
    		Antagonist 98.89%
    Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
  • HY-12405
    CGP-42112
    		Antagonist 99.84%
    CGP-42112 (CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist.
  • HY-19732
    BIBS 39
    		Antagonist 99.70%
    BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.
  • HY-13106A
    Olodanrigan sodium
    		Antagonist
    Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
  • HY-119544
    Ripisartan
    		Antagonist
    Ripisartan (UP-2696) is an angiotensin II receptor antagonist. Ripisartan is orally available. Ripisartan binds to angiotensin II receptors, dilates blood vessels, and lowers blood pressure.
  • HY-146410
    AT2R antagonist 1
    		Antagonist
    AT2R antagonist 1 (compound 21) is a potent and high selective AT2R (angiotensin II AT2 receptor) ligand. AT2R antagonist 1 exhibits a fair AT2R affinity, with a Ki of 29 nM. AT2R antagonist 1 also inhibits common agent-metabolizing CYP enzymes. AT2R antagonist 1 shows high stability in human, rat and mouse liver microsomes.
  • HY-123226
    TA-606
    		Antagonist
    TA-606 is a potent and orally active angiotensin II-receptor antagonist. TA-606 shows antihypertensive efficacy. TA-606 can be used for hypertension research.
  • HY-19202
    rac-Olodanrigan
    		Antagonist
    rac-Olodanrigan (rac-EMA401; EMA400) is a racemic mixture of the S-enantiomer (EMA401; HY-13106) and R-enantiomer (EMA402). rac-Olodanrigan is a potent and selective AT2 receptor antagonist with IC50s of 75.2 nM and 2918 nM for AT2R and AT1R, respectively. rac-Olodanrigan evokes dose-dependent relief of mechanical allodynia in the ipsilateral hind paws of rats with a chronic constriction injury (CCI) of the sciatic nerve.
  • HY-121767
    PD 123177
    		Antagonist
    PD 123177 is a nonpeptide antagonist specific for angiotensin II (AII) subtype AT2 receptor in mammalian systems.
  • HY-W098792
    Candesartan methyl ester
    		Antagonist
    Candesartan methyl ester is an antagonist for angiotensin II (AII) receptor with an IC50 of 0.11 μM. Candesartan methyl ester exhibits blood pressure lowering activity in rats models.